Reports Third Quarter GAAP EPS of
|
Three Months Ended |
|
Nine Months Ended |
|||||||||
|
|
|
|
|||||||||
|
2020 |
|
2019 |
|
2020 |
|
2019 |
|||||
|
|
|
|
|
|
|
|
|||||
|
(In millions, except per share results) |
|||||||||||
Premium Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
Total Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
Pre-Tax Income |
|
|
|
|
|
|
|
|
|
|
|
|
Net Income |
|
|
|
|
|
|
|
|
|
|
|
|
GAAP EPS – Diluted |
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted EPS – Diluted (1) |
|
|
|
|
|
|
|
|
|
|
|
|
MCR |
85.9 |
% |
|
86.3 |
% |
|
84.9 |
% |
|
85.7 |
% |
|
G&A Ratio |
7.3 |
% |
|
7.6 |
% |
|
7.3 |
% |
|
7.6 |
% |
|
Effective Tax Rate |
29.5 |
% |
|
24.7 |
% |
|
29.8 |
% |
|
24.1 |
% |
|
After-Tax Margin |
3.7 |
% |
|
4.1 |
% |
|
4.5 |
% |
|
4.5 |
% |
|
__________________ (1) See reconciliation of GAAP EPS to Non-GAAP Adjusted EPS at the end of this release. |
Highlights
-
Premium revenue was
$4.8 billion for the third quarter of 2020, a 16.8% increase compared to the third quarter of 2019. - Medical care ratio (MCR) was 85.9% for the third quarter of 2020, compared to 86.3% for the third quarter of 2019.
- General and administrative (G&A) expense ratio was 7.3% for the third quarter of 2020, a 30 basis point decrease compared to 7.6% for the third quarter of 2019.
- After-tax margin was 3.7% for the third quarter of 2020, compared to 4.1% for the third quarter of 2019.
-
Net income increased to
$185 million for the third quarter of 2020, compared to$175 million for third quarter of 2019. - The Company estimates that the net effect of COVID-19 was negligible to slightly positive to the Company’s results for the third quarter of 2020.
-
The Company’s full year GAAP earnings guidance range remains at
$11.20 to$11.70 per diluted share.
“Our third quarter performance was marked by the continued delivery of solid earnings and the focused execution of our growth strategy, all achieved in the midst of a global pandemic,” said
Recent Acquisitions
Affinity Acquisition
On
Passport Acquisition
On
Quarterly Performance Review
Premium Revenue
Premium revenue for the third quarter of 2020 increased 16.8% to
For the nine months ended
COVID-19
In the third quarter of 2020, the net effect of all COVID-related impacts, including the reduced demand for some medical services and the cost of COVID-related care, along with premium refunds and related actions, was negligible to slightly positive to the Company’s results.
Medical Care Ratio
The consolidated MCR for the third quarter of 2020 improved to 85.9%, compared to 86.3% for the third quarter of 2019.
- Medicaid MCR: Decreased to 86.4%, compared to 88.1% for the third quarter of 2019. While COVID-related impacts were slightly favorable in the Medicaid business, the Company’s performance and resulting margins still exceeded the Company’s pre-COVID expectations.
- Medicare MCR: Unchanged at 85.6%, compared to the third quarter of 2019. While COVID‑related impacts were slightly favorable in the Medicare business, the Company’s performance and resulting margins still exceeded the Company’s pre-COVID expectations.
- Marketplace MCR: Increased to 81.6%, compared to 71.2% for the third quarter of 2019. The Marketplace MCR was negatively affected by COVID-related impacts and some modest underachievement of risk scores relative to the acuity of certain Marketplace members.
The consolidated MCR for the nine months ended
General and Administrative Expense Ratio
General and administrative expenses decreased to 7.3% of total revenues for the third quarter of 2020, compared to 7.6% for the third quarter of 2019.
For the nine months ended
Balance Sheet
Cash and investments at the parent company amounted to
Cash Flow
Operating cash flows for the nine months ended
2020 Guidance
The Company has increased its full year 2020 total revenue guidance to approximately
While the Company’s core performance is expected to remain strong through the fourth quarter of 2020, the Company is choosing to maintain its existing guidance. The Company is taking this cautious approach because of the continued uncertainty related to COVID’s impact on medical care costs and the possibility for additional COVID-related rate refunds.
2021 Outlook
The Company previously provided a 2021 premium revenue outlook. That outlook included a proforma estimate of the revenue associated with its announced acquisition of Magellan Complete Care, which is on track to close around the end of the year, and an estimate of the revenue expected from auto assigned membership in its new Kentucky Medicaid contract. That outlook, which included only a modest early estimate of organic growth, was 2021 premium revenue of
The 2021 outlook has improved now that the Company currently serves all of Passport’s existing membership in
Conference Call
Management will host a conference call and webcast to discuss Molina Healthcare’s third quarter 2020 results at
About
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This earnings release and the Company’s accompanying oral remarks contain forward-looking statements regarding its 2020 guidance, as well as its plans, expectations, and the Company’s anticipation regarding future developments. Actual results could differ materially due to numerous known and unknown risks and uncertainties. These risks and uncertainties are discussed under the headings “Forward-Looking Statements” and “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended
UNAUDITED CONSOLIDATED STATEMENTS OF INCOME |
|||||||||||||||
|
Three Months Ended |
|
Nine Months Ended |
||||||||||||
|
|
|
|
||||||||||||
|
2020 |
|
2019 |
|
2020 |
|
2019 |
||||||||
|
|
|
|
|
|
|
|
||||||||
|
(In millions, except per-share amounts) |
||||||||||||||
Revenue: |
|
|
|
|
|
|
|
||||||||
Premium revenue |
$ |
4,768 |
|
|
$ |
4,084 |
|
|
$ |
13,444 |
|
|
$ |
12,085 |
|
Premium tax revenue |
170 |
|
|
119 |
|
|
477 |
|
|
367 |
|
||||
Health insurer fees reimbursed |
69 |
|
|
— |
|
|
206 |
|
|
— |
|
||||
Investment income and other revenue |
14 |
|
|
40 |
|
|
61 |
|
|
103 |
|
||||
Total revenue |
5,021 |
|
|
4,243 |
|
|
14,188 |
|
|
12,555 |
|
||||
Operating expenses: |
|
|
|
|
|
|
|
||||||||
Medical care costs |
4,098 |
|
|
3,523 |
|
|
11,412 |
|
|
10,360 |
|
||||
General and administrative expenses |
368 |
|
|
323 |
|
|
1,030 |
|
|
953 |
|
||||
Premium tax expenses |
170 |
|
|
119 |
|
|
477 |
|
|
367 |
|
||||
Health insurer fees |
70 |
|
|
— |
|
|
209 |
|
|
— |
|
||||
Depreciation and amortization |
23 |
|
|
21 |
|
|
64 |
|
|
68 |
|
||||
Other |
3 |
|
|
— |
|
|
9 |
|
|
5 |
|
||||
Total operating expenses |
4,732 |
|
|
3,986 |
|
|
13,201 |
|
|
11,753 |
|
||||
Operating income |
289 |
|
|
257 |
|
|
987 |
|
|
802 |
|
||||
Other expenses, net: |
|
|
|
|
|
|
|
||||||||
Interest expense |
27 |
|
|
22 |
|
|
72 |
|
|
67 |
|
||||
Other expense (income), net |
— |
|
|
2 |
|
|
5 |
|
|
(15) |
|
||||
Total other expenses, net |
27 |
|
|
24 |
|
|
77 |
|
|
52 |
|
||||
Income before income tax expense |
262 |
|
|
233 |
|
|
910 |
|
|
750 |
|
||||
Income tax expense |
77 |
|
|
58 |
|
|
271 |
|
|
181 |
|
||||
Net income |
$ |
185 |
|
|
$ |
175 |
|
|
$ |
639 |
|
|
$ |
569 |
|
|
|
|
|
|
|
|
|
||||||||
Net income per share - Diluted |
$ |
3.10 |
|
|
$ |
2.75 |
|
|
$ |
10.65 |
|
|
$ |
8.80 |
|
|
|
|
|
|
|
|
|
||||||||
Diluted weighted average shares outstanding |
59.6 |
|
|
63.6 |
|
|
60.0 |
|
|
64.6 |
|
||||
|
|
|
|
|
|
|
|
||||||||
Operating Statistics: |
|
|
|
|
|
|
|
||||||||
Medical care ratio |
85.9 |
% |
|
86.3 |
% |
|
84.9 |
% |
|
85.7 |
% |
||||
G&A ratio |
7.3 |
% |
|
7.6 |
% |
|
7.3 |
% |
|
7.6 |
% |
||||
Premium tax ratio |
3.4 |
% |
|
2.8 |
% |
|
3.4 |
% |
|
2.9 |
% |
||||
Effective income tax rate |
29.5 |
% |
|
24.7 |
% |
|
29.8 |
% |
|
24.1 |
% |
||||
After-tax margin |
3.7 |
% |
|
4.1 |
% |
|
4.5 |
% |
|
4.5 |
% |
CONSOLIDATED BALANCE SHEETS |
|||||||
|
|
|
|
||||
|
2020 |
|
2019 |
||||
|
Unaudited |
|
|
||||
|
(Dollars in millions,
|
||||||
ASSETS |
|||||||
Current assets: |
|
|
|
||||
Cash and cash equivalents |
$ |
3,196 |
|
|
$ |
2,452 |
|
Investments |
1,769 |
|
|
1,946 |
|
||
Receivables |
1,775 |
|
|
1,406 |
|
||
Prepaid expenses and other current assets |
213 |
|
|
163 |
|
||
Total current assets |
6,953 |
|
|
5,967 |
|
||
Property, equipment, and capitalized software, net |
395 |
|
|
385 |
|
||
|
265 |
|
|
172 |
|
||
Restricted investments |
93 |
|
|
79 |
|
||
Deferred income taxes |
74 |
|
|
79 |
|
||
Other assets |
101 |
|
|
105 |
|
||
Total assets |
$ |
7,881 |
|
|
$ |
6,787 |
|
|
|
|
|
||||
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|||||||
Current liabilities: |
|
|
|
||||
Medical claims and benefits payable |
$ |
2,289 |
|
|
$ |
1,854 |
|
Amounts due government agencies |
640 |
|
|
664 |
|
||
Accounts payable, accrued liabilities and other |
566 |
|
|
502 |
|
||
Deferred revenue |
61 |
|
|
249 |
|
||
Total current liabilities |
3,556 |
|
|
3,269 |
|
||
Long-term debt |
1,813 |
|
|
1,237 |
|
||
Finance lease liabilities |
226 |
|
|
231 |
|
||
Other long-term liabilities |
85 |
|
|
90 |
|
||
Total liabilities |
5,680 |
|
|
4,827 |
|
||
Stockholders’ equity: |
|
|
|
||||
Common stock, |
— |
|
|
— |
|
||
Preferred stock, |
— |
|
|
— |
|
||
Additional paid-in capital |
181 |
|
|
175 |
|
||
Accumulated other comprehensive income |
37 |
|
|
4 |
|
||
Retained earnings |
1,983 |
|
|
1,781 |
|
||
Total stockholders’ equity |
2,201 |
|
|
1,960 |
|
||
Total liabilities and stockholders’ equity |
$ |
7,881 |
|
|
$ |
6,787 |
|
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS |
|||||||
|
Nine Months Ended |
||||||
|
|
||||||
|
2020 |
|
2019 |
||||
|
|
|
|
||||
|
(In millions) |
||||||
Operating activities: |
|
|
|
||||
Net income |
$ |
639 |
|
|
$ |
569 |
|
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
||||
Depreciation and amortization |
64 |
|
|
68 |
|
||
Deferred income taxes |
(3) |
|
|
7 |
|
||
Share-based compensation |
43 |
|
|
29 |
|
||
Loss (gain) on debt repayment |
5 |
|
|
(15) |
|
||
Other, net |
2 |
|
|
— |
|
||
Changes in operating assets and liabilities: |
|
|
|
||||
Receivables |
(369) |
|
|
50 |
|
||
Prepaid expenses and other current assets |
(98) |
|
|
(6) |
|
||
Medical claims and benefits payable |
431 |
|
|
14 |
|
||
Amounts due government agencies |
(24) |
|
|
(355) |
|
||
Accounts payable, accrued liabilities and other |
55 |
|
|
37 |
|
||
Deferred revenue |
(188) |
|
|
(4) |
|
||
Income taxes |
34 |
|
|
4 |
|
||
Net cash provided by operating activities |
591 |
|
|
398 |
|
||
Investing activities: |
|
|
|
||||
Purchases of investments |
(670) |
|
|
(1,938) |
|
||
Proceeds from sales and maturities of investments |
891 |
|
|
1,890 |
|
||
Net cash paid in business combinations |
(62) |
|
|
— |
|
||
Purchases of property, equipment, and capitalized software |
(64) |
|
|
(30) |
|
||
Other, net |
3 |
|
|
(2) |
|
||
Net cash provided by (used in) investing activities |
98 |
|
|
(80) |
|
||
Financing activities: |
|
|
|
||||
Proceeds from senior notes offering, net of issuance costs |
789 |
|
|
— |
|
||
Repayment of term loan facility |
(600) |
|
|
— |
|
||
Common stock purchases |
(453) |
|
|
— |
|
||
Proceeds from borrowings under term loan facility |
380 |
|
|
220 |
|
||
Cash paid for partial termination of warrants |
(30) |
|
|
(514) |
|
||
Cash paid for partial settlement of conversion option |
(27) |
|
|
(578) |
|
||
Cash received for partial settlement of call option |
27 |
|
|
578 |
|
||
Repayment of principal amount of convertible senior notes |
(12) |
|
|
(240) |
|
||
Other, net |
(5) |
|
|
24 |
|
||
Net cash provided by (used in) financing activities |
69 |
|
|
(510) |
|
||
Net increase (decrease) in cash, cash equivalents, and restricted cash and cash equivalents |
758 |
|
|
(192) |
|
||
Cash, cash equivalents, and restricted cash and cash equivalents at beginning of period |
2,508 |
|
|
2,926 |
|
||
Cash, cash equivalents, and restricted cash and cash equivalents at end of period |
$ |
3,266 |
|
|
$ |
2,734 |
|
UNAUDITED HEALTH PLANS SEGMENT DATA (Dollars in millions) |
||||||||
|
|
|
|
|
|
|||
|
2020 |
|
2019 |
|
2019 |
|||
Ending Membership by Government Program: |
|
|
|
|
|
|||
Medicaid |
3,595,000 |
|
|
2,956,000 |
|
|
2,955,000 |
|
Medicare |
113,000 |
|
|
101,000 |
|
|
102,000 |
|
Marketplace |
325,000 |
|
|
274,000 |
|
|
289,000 |
|
Total |
4,033,000 |
|
|
3,331,000 |
|
|
3,346,000 |
|
|
|
|
|
|
|
|||
Ending Membership by Health Plan: |
|
|
|
|
|
|||
|
584,000 |
|
|
565,000 |
|
|
580,000 |
|
|
136,000 |
|
|
132,000 |
|
|
136,000 |
|
|
282,000 |
|
|
224,000 |
|
|
224,000 |
|
|
325,000 |
|
|
— |
|
|
— |
|
|
391,000 |
|
|
362,000 |
|
|
361,000 |
|
|
348,000 |
|
|
288,000 |
|
|
292,000 |
|
|
153,000 |
|
|
131,000 |
|
|
134,000 |
|
|
357,000 |
|
|
341,000 |
|
|
350,000 |
|
|
947,000 |
|
|
832,000 |
|
|
818,000 |
|
Other (1) |
510,000 |
|
|
456,000 |
|
|
451,000 |
|
Total |
4,033,000 |
|
|
3,331,000 |
|
|
3,346,000 |
|
__________________
(1) “Other” includes the |
|
Three Months Ended |
||||||||||||||||||||
|
2020 |
|
2019 |
||||||||||||||||||
|
Premium
|
|
Medical
|
|
MCR (1) |
|
Premium
|
|
Medical
|
|
MCR (1) |
||||||||||
|
|
|
|
|
|
||||||||||||||||
Medicaid |
$ |
3,754 |
|
|
$ |
3,245 |
|
|
86.4 |
% |
|
$ |
3,168 |
|
|
$ |
2,790 |
|
|
88.1 |
% |
Medicare |
632 |
|
|
541 |
|
|
85.6 |
|
|
559 |
|
|
479 |
|
|
85.6 |
|
||||
Marketplace |
382 |
|
|
312 |
|
|
81.6 |
|
|
357 |
|
|
254 |
|
|
71.2 |
|
||||
Consolidated |
$ |
4,768 |
|
|
$ |
4,098 |
|
|
85.9 |
% |
|
$ |
4,084 |
|
|
$ |
3,523 |
|
|
86.3 |
% |
|
Nine Months Ended |
||||||||||||||||||||
|
2020 |
|
2019 |
||||||||||||||||||
|
Premium
|
|
Medical
|
|
MCR (1) |
|
Premium
|
|
Medical
|
|
MCR (1) |
||||||||||
|
|
|
|
|
|
||||||||||||||||
Medicaid |
$ |
10,415 |
|
|
$ |
8,988 |
|
|
86.3 |
% |
|
$ |
9,239 |
|
|
$ |
8,151 |
|
|
88.2 |
% |
Medicare |
1,896 |
|
|
1,563 |
|
|
82.4 |
|
|
1,682 |
|
|
1,433 |
|
|
85.2 |
|
||||
Marketplace |
1,133 |
|
|
861 |
|
|
76.0 |
|
|
1,164 |
|
|
776 |
|
|
66.7 |
|
||||
Consolidated |
$ |
13,444 |
|
|
$ |
11,412 |
|
|
84.9 |
% |
|
$ |
12,085 |
|
|
$ |
10,360 |
|
|
85.7 |
% |
__________________ (1) The MCR represents medical costs as a percentage of premium revenue. |
CHANGE IN MEDICAL CLAIMS AND BENEFITS PAYABLE
(Dollars in millions)
The Company’s claims liabilities include additional reserves to account for moderately adverse conditions based on historical experience and other factors including, but not limited to, variations in claims payment patterns, changes in utilization and cost trends, known outbreaks of disease, and large claims. The Company’s reserving methodology is consistently applied across all periods presented. The amounts displayed for “Components of medical care costs related to: Prior year” represent the amounts by which the original estimates of claims and benefits payable at the beginning of the year were more than the actual liabilities based on information (principally the payment of claims) developed since those liabilities were first reported. The following table presents the components of the change in medical claims and benefits payable for the periods indicated:
|
Nine Months Ended |
|
Year Ended
|
||||||||
|
|
|
|||||||||
|
2020 |
|
2019 |
|
|||||||
|
|
|
|
|
|
||||||
|
Unaudited |
|
|
||||||||
Medical claims and benefits payable, beginning balance |
$ |
1,854 |
|
|
$ |
1,961 |
|
|
$ |
1,961 |
|
Components of medical care costs related to: |
|
|
|
|
|
||||||
Current year |
11,478 |
|
|
10,613 |
|
|
14,176 |
|
|||
Prior year |
(66) |
|
|
(253) |
|
|
(271) |
|
|||
Total medical care costs |
11,412 |
|
|
10,360 |
|
|
13,905 |
|
|||
Change in non-risk and other provider payables |
50 |
|
|
131 |
|
|
24 |
|
|||
Payments for medical care costs related to: |
|
|
|
|
|
||||||
Current year |
9,500 |
|
|
8,996 |
|
|
12,554 |
|
|||
Prior year |
1,527 |
|
|
1,481 |
|
|
1,482 |
|
|||
Total paid |
11,027 |
|
|
10,477 |
|
|
14,036 |
|
|||
Medical claims and benefits payable, ending balance |
$ |
2,289 |
|
|
$ |
1,975 |
|
|
$ |
1,854 |
|
|
|
|
|
|
|
||||||
Days in claims payable, fee for service (1) |
52 |
|
|
50 |
|
|
50 |
|
______________________
(1) Claims payable includes primarily claims incurred but not paid, or IBNP. It also includes certain fee-for-service payables reported in medical claims and benefits payable amounting to |
RECONCILIATION OF UNAUDITED NON-GAAP FINANCIAL MEASURES
(In millions)
The Company believes that certain non-generally accepted accounting principles, or non-GAAP, financial measures are useful supplemental measures to investors in comparing the Company’s performance to the performance of other public companies in the health care industry. These non‑GAAP financial measures, presented below, should be considered as supplements to, and not as substitutes for or superior to, GAAP measures.
Earnings before interest, taxes, depreciation and amortization (“EBITDA”): GAAP net income less depreciation and amortization, interest expense and income tax expense. The Company believes that EBITDA is helpful to investors in assessing the Company’s ability to meet the cash demands of its operating units.
|
Three Months Ended |
|
Nine Months Ended |
||||||||||||
|
|
|
|
||||||||||||
|
2020 |
|
2019 |
|
2020 |
|
2019 |
||||||||
Net income |
$ |
185 |
|
|
$ |
175 |
|
|
$ |
639 |
|
|
$ |
569 |
|
Adjustments: |
|
|
|
|
|
|
|
||||||||
Depreciation and amortization |
23 |
|
|
21 |
|
|
64 |
|
|
68 |
|
||||
Interest expense |
27 |
|
|
22 |
|
|
72 |
|
|
67 |
|
||||
Income tax expense |
77 |
|
|
58 |
|
|
271 |
|
|
181 |
|
||||
EBITDA |
$ |
312 |
|
|
$ |
276 |
|
|
$ |
1,046 |
|
|
$ |
885 |
|
RECONCILIATION OF UNAUDITED NON-GAAP FINANCIAL MEASURES CONTINUED
(In millions, except per diluted share amounts)
Adjusted net income: GAAP net income less amortization of intangible assets, premium deficiency reserves relating to the Company’s exit of the Puerto Rico Medicaid market, restructuring costs, loss (gain) on debt repayment, acquisition-related expenses (beginning in the third quarter of 2020), and the aggregate income tax effect calculated at the blended federal and state statutory tax rate. The Company believes that adjusted net income is helpful to investors in assessing the Company’s financial performance exclusive of the non-cash impact of the amortization of purchased intangibles and the impact of certain expenses and other items that management believes are not indicative of longer-term business trends and operations.
Adjusted net income per diluted share: Adjusted net income divided by weighted average common shares outstanding on a fully diluted basis. Source data for the calculations is in thousands.
|
Three Months Ended |
|
Nine Months Ended |
||||||||||||||||||||||||||||
2020 |
|
2019 |
|
2020 |
|
2019 |
|||||||||||||||||||||||||
|
Amount |
|
Per
|
|
Amount |
|
Per
|
|
Amount |
|
Per
|
|
Amount |
|
Per
|
||||||||||||||||
Net income |
$ |
185 |
|
|
$ |
3.10 |
|
|
$ |
175 |
|
|
$ |
2.75 |
|
|
$ |
639 |
|
|
$ |
10.65 |
|
|
$ |
569 |
|
|
$ |
8.80 |
|
Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Amortization of intangible assets |
4 |
|
|
0.06 |
|
|
4 |
|
|
0.07 |
|
|
12 |
|
|
0.19 |
|
|
13 |
|
|
0.21 |
|
||||||||
Premium deficiency reserve - |
10 |
|
|
0.17 |
|
|
— |
|
|
— |
|
|
10 |
|
|
0.17 |
|
|
— |
|
|
— |
|
||||||||
Restructuring costs |
3 |
|
|
0.04 |
|
|
— |
|
|
— |
|
|
9 |
|
|
0.15 |
|
|
5 |
|
|
0.08 |
|
||||||||
Loss (gain) on debt repayment |
— |
|
|
— |
|
|
2 |
|
|
0.04 |
|
|
5 |
|
|
0.08 |
|
|
(15) |
|
|
(0.24) |
|
||||||||
Acquisition-related expenses (1) |
4 |
|
|
0.07 |
|
|
— |
|
|
— |
|
|
4 |
|
|
0.06 |
|
|
— |
|
|
— |
|
||||||||
Subtotal, adjustments |
21 |
|
|
0.34 |
|
|
6 |
|
|
0.11 |
|
|
40 |
|
|
0.65 |
|
|
3 |
|
|
0.05 |
|
||||||||
Income tax effect |
(5) |
|
|
(0.08) |
|
|
(1) |
|
|
(0.03) |
|
|
(9) |
|
|
(0.15) |
|
|
(1) |
|
|
(0.01) |
|
||||||||
Adjustments, net of tax |
16 |
|
|
0.26 |
|
|
5 |
|
|
0.08 |
|
|
31 |
|
|
0.50 |
|
|
2 |
|
|
0.04 |
|
||||||||
Adjusted net income |
$ |
201 |
|
|
$ |
3.36 |
|
|
$ |
180 |
|
|
$ |
2.83 |
|
|
$ |
670 |
|
|
$ |
11.15 |
|
|
$ |
571 |
|
|
$ |
8.84 |
|
______________________ (1) Beginning in the third quarter of 2020, reflects non-recurring costs associated with acquisitions, including various transaction and integration costs. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20201028006048/en/
Investor Contact:
Media Contact:
Source: